# Venlafaxine Augmentation in Treatment Resistant Depression

> **NCT00253266** · PHASE4 · COMPLETED · sponsor: **Max-Planck-Institute of Psychiatry** · enrollment: 126 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Venlafaxine
- **DRUG:** Quetiapine

## Key facts

- **NCT ID:** NCT00253266
- **Lead sponsor:** Max-Planck-Institute of Psychiatry
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-08
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2015-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253266, "Venlafaxine Augmentation in Treatment Resistant Depression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00253266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*